Compare MTEX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTEX | GDTC |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.4M |
| IPO Year | 1998 | 2021 |
| Metric | MTEX | GDTC |
|---|---|---|
| Price | $6.97 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.0K | ★ 24.4K |
| Earning Date | 04-15-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | ★ $108,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.80 | $0.68 |
| 52 Week High | $12.45 | $3.68 |
| Indicator | MTEX | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 65.05 | 51.28 |
| Support Level | $6.94 | $0.93 |
| Resistance Level | $7.68 | $1.09 |
| Average True Range (ATR) | 0.52 | 0.09 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 93.64 | 63.33 |
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.